Cim Investment Mangement Inc. lessened its position in Allergan plc (NYSE:AGN) by 3.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,405 shares of the company’s stock after selling 138 shares during the period. Cim Investment Mangement Inc.’s holdings in Allergan were worth $455,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ruggie Capital Group bought a new position in shares of Allergan in the fourth quarter worth approximately $53,000. Dubuque Bank & Trust Co. lifted its position in Allergan by 6,457.1% during the fourth quarter. Dubuque Bank & Trust Co. now owns 459 shares of the company’s stock valued at $61,000 after purchasing an additional 452 shares during the period. IMS Capital Management bought a new position in Allergan during the third quarter valued at approximately $66,000. Quantamental Technologies LLC bought a new position in Allergan during the fourth quarter valued at approximately $67,000. Finally, Exane Asset Management bought a new position in Allergan during the fourth quarter valued at approximately $77,000. Hedge funds and other institutional investors own 84.04% of the company’s stock.

Allergan stock opened at $132.09 on Monday. The stock has a market capitalization of $44.55 billion, a PE ratio of 7.91, a PEG ratio of 1.05 and a beta of 1.43. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.51 and a quick ratio of 1.34. Allergan plc has a 12-month low of $125.84 and a 12-month high of $197.00.

Allergan (NYSE:AGN) last released its earnings results on Tuesday, January 29th. The company reported $4.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.15 by $0.14. Allergan had a negative net margin of 32.28% and a positive return on equity of 8.18%. The firm had revenue of $4.08 billion during the quarter, compared to analyst estimates of $4 billion. During the same quarter last year, the business earned $4.86 EPS. The business’s revenue was down 5.7% on a year-over-year basis. Research analysts forecast that Allergan plc will post 16.34 EPS for the current year.

Allergan declared that its Board of Directors has initiated a share repurchase program on Tuesday, January 29th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 4.1% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 15th. Shareholders of record on Friday, February 15th will be given a dividend of $0.74 per share. This is an increase from Allergan’s previous quarterly dividend of $0.72. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $2.96 dividend on an annualized basis and a yield of 2.24%. Allergan’s dividend payout ratio (DPR) is 17.26%.

In other Allergan news, CFO Matthew M. Walsh bought 1,000 shares of the business’s stock in a transaction on Friday, November 16th. The shares were acquired at an average price of $157.00 per share, with a total value of $157,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.37% of the company’s stock.

AGN has been the topic of a number of research analyst reports. Credit Suisse Group set a $200.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Thursday, December 13th. Royal Bank of Canada set a $220.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Friday, November 30th. Wells Fargo & Co restated a “buy” rating on shares of Allergan in a research report on Wednesday, October 17th. Cowen set a $255.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Wednesday, October 17th. Finally, Raymond James decreased their price target on shares of Allergan from $232.00 to $198.00 and set a “buy” rating on the stock in a research report on Wednesday, October 31st. Two analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $201.37.

COPYRIGHT VIOLATION NOTICE: “Cim Investment Mangement Inc. Has $455,000 Stake in Allergan plc (AGN)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Further Reading: What is Compound Annual Growth Rate (CAGR)?

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with's FREE daily email newsletter.